Uveitis Market

DelveInsight’s ‘Uveitis-Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Uveitis, historical and forecasted epidemiology as well as the Uveitis market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


The Uveitis market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Uveitis market size from 2017 to 2030. The Report also covers current Uveitis treatment practice/algorithm, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017–2030

Uveitis Disease Understanding and Treatment Algorithm

Uveitis Overview

Prevent Blindness Organization defines Uveitis as, a term for inflammation of the eye. It is an inflammation of the uvea, the pigmented layer that lies between the inner retina and the outer fibrous layer composed of the sclera and cornea. Uvea is made up of the iris, ciliary body and choroid.


Uveitis is caused by inflammatory responses inside the eye that can be caused due to tissue damage, germs, or toxins which lead swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part.


Uveitis can affect anyone at any age, but it is most commonly seen in working-age adults in their fourth decade. There is a higher prevalence in women. Uveitis is classified anatomically as anterior, intermediate, posterior, or diffuse. Anterior uveitis typically refers to inflammation of the iris and anterior chamber; intermediate uveitis refers to inflammation of the ciliary body and vitreous humor (the jellylike filling in the anterior portion of the eye); and posterior uveitis refers to inflammation of the retina, choroid, or the optic disk (where the optic nerve enters the retina). Diffuse uveitis (panuveitis) implies inflammation of the entire uveal tract.

Uveitis Diagnosis

A uveitis diagnosis requires a thorough examination by an ophthalmologist, including a detailed look into the past and present health history. Uveitis can be suspected in any patient who has ocular ache, redness, photophobia, floaters, or decreased vision. It is diagnosed by eye chart or visual acuity test, funduscopic exam, ocular pressure test, and slit lamp exam.

Continued in the report…..

Uveitis Treatment

Treatment for Uveitis aims to help relieve pain and discomfort in the eye, underlying cause, and reduction in inflammation that can prevent permanent loss of vision or other complications. The primary goal of treating uveitis is to get rid of inflammation as fast as possible.


Corticosteroids are the first-line therapy of the treatment of ocular inflammatory diseases. In the United States, corticosteroids are the drugs that are approved as first-line treatment by the US FDA for the treatment of ocular inflammatory diseases in the form of topical administration or sustained intravitreal implants. The approved corticosteroid and combination drugs include Durezol, Triesence, Retisert, Iluvien, Tobradex, Yutiq, and Ozurdex. Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment of severe acute and chronic allergic and inflammatory processes.


Immunosuppressants such as azathioprine, methotrexate, mycophenolate Mofetil, and cyclosporine are considered as the second line of therapy. The appropriate treatment and choice of immunosuppressive therapy of Uveitis depend on both the extent and severity of the inflammatory process.


Biologics are being used as the third line of therapy to treat Uveitis that fails to induce a response to conventional forms of immunosuppression. Among them, Humira (Adalimumab) is the first human monoclonal antibody being approved for the Uveitis. Approval of Humira in the United States, Europe and Japan is a major advancement in improving the existing standards of care for patients. Several off-label biologics such as Etanercept, Infliximab, Tocilizumab, and Certolizumab are used for Uveitis

Uveitis Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Population of Uveitis, Diagnosed Prevalent Population of Uveitis, Gender-specific Diagnosed Prevalent Population of Uveitis, Age-specific Diagnosed Prevalent Population of Uveitis, Type-specific Diagnosed Prevalent Population of Uveitis, Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location, and Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) scenario of uveitis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.

Key Findings

  • As per DelveInsight’s analysis, the total Prevalent Population of Uveitis in the 7MM was found to be 897,466 in 2017. The estimates higher prevalence of Uveitis in the United States with 357,791 cases in 2017.
  • Among the European countries, Germany had the maximum prevalent population of Uveitis with 93,260 cases followed by France, which had a prevalent population of 77,331 in 2017.
  • In 2017, it was found that there were 28,111 diagnosed cases of infectious uveitis, and 293,901 cases of non-infectious uveitis in the United States.
  • In 2017, Acute Anterior Uveitis was accounted for 43.00% of the total cases of Uveitis in the United States. Acute anterior noninfectious uveitis includes Grade 0 and 1, and accounts for 98,670 cases in 2017. While, in the same year, 130,795 cases of chronic anterior noninfectious uveitis out of which Grade 2 has 84,581 cases; Grade 3 has 31,528; and Grade 4 has 14,686 cases respectively.
  • Japan accounts second among the 7MM in terms of prevalent cases with 166,478 cases among the 7MM.

Uveitis Epidemiology

The epidemiology segment also provides the Uveitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Uveitis Drug Chapters

The drug chapter segment of the Uveitis report encloses the detailed analysis of Uveitis marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Uveitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug and the latest news and press releases.

Uveitis Marketed Drugs

Durezol: Sirion Therapeutics

Durezol (Alcon Pharmaceuticals/ Sirion Therapeutics) is a corticosteroid ophthalmic emulsion, indicated for the treatment of postoperative ocular inflammation and pain, and endogenous Anterior Uveitis. Its active pharmaceutical ingredient is Difluprednate, which is structurally similar to other corticosteroids. It is a glucocorticoid receptor agonist. There is no clear explanation of the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid.

Products detail in the report…

Triesence: Novartis

Triesence is a commercially available preservative-free preparation of triamcinolone acetonide which is approved for intraocular use in the treatment of Uveitis, certain types of eye inflammation unresponsive to topical corticosteroids, sympathetic ophthalmia. The drug is also approved for use in assisting with visualization during vitrectomy.

Products detail in the report…

Retisert: Valeant Pharmaceuticals International Inc

Retisert (fluocinolone acetonide implant) is an intravitreal implant co-developed by Bausch & Lomb (acquired by Valeant Pharmaceuticals International Inc.) and pSivida of the treatment of Non-infectious Uveitis. The implant was developed by using Bausch & Lomb's Envision TD technology. It can deliver 0.59mg of the corticosteroid fluocinolone acetonide to Posterior eye tissue of up to 2.5 years. It has been launched in the US but failed to get marketing approval in the EU because the application was withdrawn after the company was unable to provide additional information to regulatory authorities, regarding the dosing and efficacy of the product. The development of the implant of the treatment of macular edema and age-related macular degeneration have been discontinued, reasons undisclosed.

Products detail in the report…

List to be continued in the report…

Uveitis Emerging Drugs

Reproxalap/ADX-102: Aldeyra Therapeutics

Reproxalap/ADX-102 (also known as NS-2-Aldeyra; NS 2) is under the development by Aldeyra Therapeutics. It is a novel small molecule that covalently binds aldehydes including malondialdehyde and 4-hydroxynonenal, which have been shown to mediate inflammatory pain. The drug candidate is in the Phase III stage of development for the treatment of Noninfectious Anterior Uveitis (NAU). It is also in the Phase II stage of development for allergic conjunctivitis and dry eye syndrome. It is in the pre-clinical stage of development for SSADH Deficiency. It acts by binding to aldehydes. The drug candidate is being developed by using Aldeyra's aldehyde trap platform sequester.

Products detail in the report…

Sirolimus: Santen

Sirolimus is under development by Santen Pharmaceutical. The therapeutic candidate is filed for the treatment of Non-Infectious Uveitis of the Posterior Segment (NIU-PS) in the United States and Asia. The therapeutic candidate is in Phase III stage of development for the treatment of Uveitis in Europe and Japan. Sirolimus, also known as rapamycin, is a macrolide antibiotic that exerts its immunosuppressive effects by inhibiting the mammalian target of rapamycin mTOR kinase. Sirolimus is delivered by intravitreal injection. It is also found that intravitreal sirolimus reduces vitreous haze in eyes significantly in case of noninfectious Uveitis of the posterior segment, preserves vision, and has an acceptable safety profile.

Products detail in the report…

EGP-437: EyeGate Pharmaceuticals

EGP-437 is under development by EyeGate Pharma. The drug candidate is in Phase III stage of development for the treatment of Anterior Uveitis. The drug candidate is a small molecule that contains Dexamethasone phosphate ophthalmic solution delivered by the EyeGate II Drug Delivery System. EGP-437 is a needle-free treatment of eye inflammation treatments. EyeGate II Delivery System utilizes a low-level electrical current to deliver a specified amount of drug for each treatment. It is powered by iontophoresis, this non-invasive delivery method mitigates many of the non-compliance and other risks of topical administration (drops) as well as the safety issues and challenges of invasive treatments (injection).

Products detail in the report…

List to be continued in the report…

Uveitis Market Outlook

United States contributes to the major share of the Uveitis market as compared to other countries, such as EU5 (Italy, Spain, United Kingdom, France, and Germany) and Japan. The high prevalence of Uveitis in the United States is a major factor in stimulating market growth.


The Standardization of Uveitis Nomenclature Working Group Guidelines recommends the use of corticosteroids as first-line therapy for patients with active uveitis. However, long-term corticosteroid treatment can cause serious systemic and ocular side effects, such as hypertension, diabetes, cataract, and glaucoma. Alternatively, immunomodulatory therapy (IMT) drugs are given as steroid-sparing agents and have shown good clinical results for both systemic diseases and ocular inflammatory diseases. IMT agents include the antimetabolites methotrexate, azathioprine, and mycophenolate mofetil; the calcineurin inhibitors that include cyclosporine, tacrolimus, and sirolimus; alkylating agents that include cyclophosphamide and chlorambucil; biologic response modifiers that include the tumor necrosis factor (TNF)-α inhibitors infliximab, adalimumab, etanercept, golimumab, and certolizumab; lymphocyte inhibitors that include daclizumab, rituximab, abatacept, and basiliximab; specific receptor antagonists that include anakinra, canakinumab, gevokizumab, tocilizumab, alemtuzumab, efalizumab, secukinumab, and ustekinumab; and interferon (INF).


Fluocinolone acetonide (Retisert) and dexamethasone (Ozurdex) are the two corticosteroid compounds in the FDA approved intraocular implants. Two sustained-release corticosteroid potent implants– Retisert and Ozurdex are approved for the treatment of Posterior Uveitis. Use of immunosuppressive agents such as Methotrexate, Azathioprine, Mycophenolate Mofetil, and Cyclosporine being used for preventing ocular inflammation and off-labels biologics such as Infliximab are also fueling the growth of mark and also act as market drivers. Approval of Humira in the United States, Europe and Japan is a major advancement in improving the existing standards of care for patients.


The approved corticosteroid and combination drugs include Durezol, Triesence, Retisert, Iluvien, Tobradex, Yutiq, Acthar Gel, and Ozurdex.


According to DelveInsight, Uveitis 7MM is expected to change in the study period 2017–2030.

Key Findings

  • The market size of Uveitis in the 7MM was found to be USD 1,045.9 million in 2017.
  • Among the EU5 countries, Germany had the highest market size worth USD 80.5 million in 2017, while Spain had the lowest market size of Uveitis valued at USD 48.7 million in 2017.
  • Amongst the therapeutic class, the corticosteroids hold the highest patient share amongst the other therapeutic options available for the treatment of Uveitis.

The United States Market Outlook

This section provides the total Uveitis market size and; market size by therapies in the United States.

EU-5 Market Outlook

The total Uveitis market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Uveitis market size and market size by therapies in Japan are provided.

Uveitis Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Uveitis market or expected to get launched in the market during the study period 2017–2030. The analysis covers Uveitis market uptake by drugs; patient uptake by therapies; and sales of each drug.  

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Uveitis Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for Uveitis emerging therapies.

Reimbursement Scenario in Uveitis

In June 2019, United Kingdom’s National Institute for Health and Care Excellence (NICE), in its Final Appraisal Determination for national reimbursement, had recommended funding for Iluvien 190 mg intravitreal implant in the applicator for the prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment (NIPU). The NICE recommendation for funding signifies that the country’s National Health Service (NHS) will pay for Iluvien prescriptions for the treatment of NIPU as part of its offering (Bloomberg, 2019). In Japan, the patients pay between 10–30% of the cost of biologicals and biosimilars. The rest of the amount is funded by the insurance companies or government.


In the UK, Alimera has been engaged with NICE to determine the cost-effectiveness of Iluvien for NIPU’s treatment. The assessment to date has been a nonpublic process and is ongoing. Alimera anticipated that NICE will provide a public response soon and would require the submission of additional data and modeling to the appraisal committee to substantiate ILUVIEN’s cost-effectiveness, and further evaluation, before a public committee meeting in May 2019. This assessment process had no effect on any private payer use following the national phase nor on NICE’s previous agreement to fund the treatment of pseudophakic eyes in chronic diabetic macular edema patients that are insufficiently responsive to available therapies.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Uveitis market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of Uveitis, explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
  • Comprehensive insight has been provided into the Uveitis epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Uveitis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the Uveitis market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Uveitis market.

Report Highlights

  • The rich emerging pipeline, advancement in the treatment, increasing awareness for the disease, growing population of females in the reproductive age group and availability of better symptom control medications will positively drive the Uveitis market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Uveitis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for Uveitis. Launch of emerging therapies will significantly impact the Uveitis market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Uveitis Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Uveitis Pipeline Analysis
  • Uveitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Uveitis Report Key Strengths

  • Eleven Years Forecast
  • 7MM Coverage
  • Uveitis Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Uveitis Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the Uveitis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Uveitis total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest Uveitis market size during the forecast period (2020–2030)?
  • At what CAGR, the Uveitis market is expected to grow at the 7MM level during the forecast period (2020–2030)?
  • What would be the Uveitis market outlook across the 7MM during the forecast period (2020–2030)?
  • What would be the Uveitis market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of Uveitis?
  • What is the historical Uveitis patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
  • What would be the forecasted patient pool of Uveitis at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Uveitis?
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Uveitis during the forecast period (2020–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of Uveitis along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Uveitis in the US and Europe?
  • What are the Uveitis marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Uveitis?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of Uveitis?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Uveitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Uveitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Uveitis?
  • What are the 7MM historical and forecasted market of Uveitis?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Uveitis.
  • To understand the future market competition in the Uveitis market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for Uveitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the Uveitis market.
  • To understand the future market competition in the Uveitis market.

 

1. Key Insight

2. Executive Summary

3. Uveitis Market Overview at a Glance

3.1. Market Share (%) Distribution of Uveitis in 2017

3.2. Market Share (%) Distribution of Uveitis in 2030

4. Disease Background and Overview: Uveitis

4.1. Introduction

4.2. Classification of Uveitis

4.3. International Uveitis Study Group (IUSG) Clinical Classification of Uveitis

4.4. The Standardization of Uveitis Nomenclature (SUN) Working Group

4.5. Symptoms of Uveitis

4.6. Pathophysiology

4.7. Etiology of Uveitis

4.8. Diagnosis of Uveitis

American Academy of Family Physicians

5. Case Reports

5.1. A Case Study of Unusual Etiology of Anterior Uveitis with Ocular Hypertension-Iris Metastasis of Primary Lung Adenocarcinoma

5.2. Blurry Vision and a Black Ink Tattoo

5.3. Psoriatic Juvenile Idiopathic Arthritis Associated with Uveitis: A Case Report

5.4. A Case of Syphilitic Uveitis in Which Vitreous Surgery Was Useful for the Diagnosis and Treatment

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Epidemiology Methodology

6.3. Prevalent Population of Uveitis in the 7MM

6.4. Diagnosed Prevalent Population of Uveitis in the 7MM

6.5. Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM

7. United States-Epidemiology of Uveitis

7.1. Assumptions and Rationale

7.2. Total Prevalent Population of Uveitis in the United States

7.3. Diagnosed Prevalent Population of Uveitis in the United States

7.4. Gender-specific Diagnosed Prevalent Population of Uveitis in the United States

7.5. Age-specific Diagnosed Prevalent Population of Uveitis in the United States

7.6. Type-specific Diagnosed Prevalent Population of Uveitis in the United States

7.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

7.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States

8. EU-5 Epidemiology of Uveitis

8.1. Germany

8.1.1. Assumptions and Rationale

8.1.2. Prevalent Population of Uveitis in Germany

8.1.3. Diagnosed Prevalent Population of Uveitis in Germany

8.1.4. Gender-specific Diagnosed Prevalence of Uveitis in Germany

8.1.5. Age-specific Diagnosed Prevalence of Uveitis in Germany

8.1.6. Type-specific Diagnosed Prevalence of Uveitis in Germany

8.1.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

8.1.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany

8.2. France

8.2.1. Assumptions and Rationale

8.2.2. Prevalent Population of Uveitis in France

8.2.3. Diagnosed Prevalent Population of Uveitis in France

8.2.4. Gender-specific Diagnosed Prevalence of Uveitis in France

8.2.5. Age-specific Diagnosed Prevalence of Uveitis in France

8.2.6. Type-specific Diagnosed Prevalence of Uveitis in France

8.2.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

8.2.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France

8.3. Italy

8.3.1. Assumptions and Rationale

8.3.2. Prevalent Population of Uveitis in Italy

8.3.3. Diagnosed Prevalent Population of Uveitis in Italy

8.3.4. Gender-specific Diagnosed Prevalence of Uveitis in Italy

8.3.5. Age-specific Diagnosed Prevalence of Uveitis in Italy

8.3.6. Type-specific Diagnosed Prevalence of Uveitis in Italy

8.3.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location

8.3.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy

8.4. Spain

8.4.1. Assumptions and Rationale

8.4.2. Prevalent Population of Uveitis in Spain

8.4.3. Diagnosed Prevalent Population of Uveitis in Spain

8.4.4. Gender-specific Diagnosed Prevalence population of Uveitis in Spain

8.4.5. Age-specific Diagnosed Prevalence of Uveitis in Spain

8.4.6. Type-specific Diagnosed Prevalence of Uveitis in Spain

8.4.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain

8.4.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain

8.5. United Kingdom

8.5.1. Assumptions and Rationale

8.5.2. Prevalent Population of Uveitis in the UK

8.5.3. Diagnosed Prevalent Population of Uveitis in the United Kingdom

8.5.4. Gender-specific Diagnosed Prevalence of Uveitis in the UK

8.5.5. Age-specific Diagnosed Prevalence of Uveitis in the UK

8.5.6. Type-specific Diagnosed Prevalence of Uveitis in the UK

8.5.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK

8.5.8. Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK

9. Japan

9.1. Assumptions and Rationale

9.2. Prevalent Population of Uveitis in Japan

9.3. Diagnosed Prevalent Population of Uveitis in Japan

9.4. Gender-specific Prevalence of Uveitis in Japan

9.5. Age-specific Prevalence of Uveitis in Japan

9.6. Type-specific Prevalence of Uveitis in Japan

9.7. Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan

9.8. Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan

10. Treatment of Uveitis

10.1. Treatment Algorithm

10.2. First Line of Therapy: Corticosteroids

10.3. Second Line of Therapy: Immunosuppressants

10.4. Third Line of Therapy: Biologics

10.5. Guidance on Noncorticosteroid Systemic Immunomodulatory Therapy in Noninfectious Uveitis: Fundamentals of Care for Uveitis (FOCUS) Initiative

11. Unmet Needs

12. Marketed Drugs

12.1. Key Cross Competition

12.2. Durezol: Sirion Therapeutics

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Advantages & Disadvantages

12.2.4. Safety and Efficacy

12.2.5. Product Profile

12.3. Triesence: Novartis

12.3.1. Drug Description

12.3.2. Regulatory Milestones

12.3.3. Advantages & Disadvantages

12.3.4. Safety and Efficacy

12.3.5. Product Profile

12.4. Retisert: Valeant Pharmaceuticals International Inc

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Advantages & Disadvantages

12.4.4. Safety

12.4.5. Efficacy

12.4.6. Product Profile

12.5. Ozurdex: Allergan plc

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Advantages and Disadvantages

12.5.4. Efficacy

12.5.5. Safety

12.5.6. Product Profile

12.6. Humira: AbbVie Inc.

12.6.1. Drug Description

12.6.2. Regulatory Milestones

12.6.3. Advantages & Disadvantages

12.6.4. Safety and Efficacy

12.6.5. Product Profile

12.7. Yutiq: Eyepoint Pharmaceuticals

12.7.1. Product Description

12.7.2. Regulatory Milestones

12.7.3. Clinical Development

12.7.4. Advantages & Disadvantages

12.7.5. Safety and Efficacy

12.7.6. Product Profile

12.8. Tobradex: Alcon Laboratories

12.8.1. Product Description

12.8.2. Other Developmental Activities

12.8.3. Product Profile

12.9. Acthar: Mallinckrodt

12.9.1. Product Description

12.9.2. Other Developmental Activities

12.9.3. Advantages and Disadvantages

12.9.4. Safety and Efficacy

12.9.5. Product Profile

12.10. Iluvien: Alimera Sciences

12.10.1. Product Description

12.10.2. Other Developmental Activities

12.10.3. Clinical Development

12.10.4. Clinical Trials Information

12.10.5. Safety and Efficacy

12.10.6. Product Profile

13. Emerging Drugs Analysis

13.1. Key Cross Competition

13.2. Reproxalap/ADX-102: Aldeyra Therapeutics Inc.

13.2.1. Product Description

13.2.2. Advantages and Disadvantages

13.2.3. Clinical Development

13.2.4. Safety and Efficacy

13.2.5. Product Profile

13.3. Sirolimus: Santen

13.3.1. Product Description

13.3.2. Regulatory Milestones

13.3.3. Advantages and Disadvantages

13.3.4. Clinical Development

13.3.5. Safety and Efficacy

13.3.6. Product Profile

13.4. EGP-437: EyeGate Pharmaceuticals

13.4.1. Product Description

13.4.2. Regulatory Milestones

13.4.3. Advantages and Disadvantages

13.4.4. Clinical Development

13.4.5. Safety and Efficacy

13.4.6. Product Profile

13.5. XIPERE/Suprachoroidal CLS-TA: Clearside Biomedical, Inc.

13.5.1. Product Description

13.5.2. Regulatory Milestones

13.5.3. Clinical Development

13.5.4. Safety and Efficacy

13.5.5. Product Profile

13.6. Sarilumab: Sanofi Aventis

13.6.1. Product Description

13.6.2. Product Development Activities

13.6.3. Advantages and Disadvantages

13.6.4. Clinical Development

13.6.5. Safety and Efficacy

13.6.6. Product Profile

13.7. LME636 (OCS-02): Oculis Pharma

13.7.1. Product Description

13.7.2. Other development activities

13.7.3. Clinical Development

13.7.4. Safety and Efficacy

13.7.5. Product Profile

13.8. LFG316: Novartis

13.8.1. Product Description

13.8.2. Other development activities

13.8.3. Clinical Development

13.8.4. Safety and Efficacy

13.8.5. Product Profile

13.9. Abatacept (Orenica): Bristol-Myers Squibb Company

13.9.1. Product Description

13.9.2. Clinical Development

13.9.3. Safety and Efficacy

13.9.4. Product Profile

13.10. EYS606: Eyevensys

13.10.1. Product Description

13.10.2. Other development activities

13.10.3. Clinical Development

13.10.4. Safety and Efficacy

13.10.5. Product Profile

14. Uveitis: Seven Major Market Analysis

14.1. Key Findings

14.2. Market Size of Uveitis in the 7MM

14.3. Market Size of Uveitis by Therapies in the 7MM

15. United States: Market Outlook

15.1. Total Market size of Uveitis

15.2. Uveitis Market Size by Therapies

16. EU5: Market Outlook

16.1. Germany Market Size

16.1.1. Total Market size of Uveitis

16.1.2. Uveitis Market Size by Therapies

16.2. France Market Size

16.2.1. Total Market size of Uveitis

16.2.2. Uveitis Market Size by Therapies

16.3. Italy Market Size

16.3.1. Total Market size of Uveitis

16.3.2. Uveitis Market Size by Therapies

16.4. Spain Market Size

16.4.1. Total Market size of Uveitis

16.4.2. Uveitis Market Size by Therapies

16.5. United Kingdom Market Size

16.5.1. Total Market size of Uveitis

16.5.2. Uveitis Market Size by Therapies

17. Japan: Market Outlook

17.1. Japan: Market Size

17.1.1. Total Market size of Uveitis

17.1.2. Uveitis Market Size by Therapies

18. Market Drivers

19. Market Barriers

20. Reimbursement and Market Access

21. KOL Views

22. Appendix

23. Report Methodology

23.1. Sources Used

24. DelveInsight Capabilities

25. Disclaimer

26. About DelveInsight

List of Tables

 Table 1 Summary of Uveitis, Market, Epidemiology and Key Events (2017–2030)

Table 2 IUSG Clinical Classification of Uveitis

Table 3 The SUN Working Group Anatomic Classification of Uveitis

Table 4 The SUN Working Group Descriptors of Uveitis

Table 5 The SUN Working Group Grading Scheme for Anterior Chamber Cells

Table 6 The SUN Working Group Grading Scheme for Anterior Chamber Cells

Table 7 KEY RECOMMENDATIONS FOR PRACTICE

Table 8 Region-wise Prevalent Population of Uveitis (2017–2030)

Table 9 Diagnosed Prevalent Population of Uveitis (2017–2030)

Table 10 Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)

Table 11 Total Prevalent Population of Uveitis in the US (2017–2030)

Table 12 Total Diagnosed Prevalent Population of Uveitis in the US (2017–2030)

Table 13 Gender-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)

Table 14 Age-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)

Table 15 Type-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)

Table 16 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2030)

Table 17 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2030)

Table 18 Prevalent Population of Uveitis in Germany (2017–2030)

Table 19 Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Table 20 Gender-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Table 21 Age-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Table 22 Type-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Table 23 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2030)

Table 24 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany (2017–2030)

Table 25 Prevalent Population of Uveitis in France (2017–2030)

Table 26 Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Table 27 Gender-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Table 28 Age-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Table 29 Type-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Table 30 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2030)

Table 31 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2030)

Table 32 Prevalent Population of Uveitis in Italy (2017–2030)

Table 33 Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Table 34 Gender-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Table 35 Age-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Table 36 Type-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Table 37 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2030)

Table 38 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2030)

Table 39 Prevalent Population of Uveitis in Spain (2017–2030)

Table 40 Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Table 41 Gender-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Table 42 Age-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Table 43 Type-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Table 44 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2030)

Table 45 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2030)

Table 46 Prevalent Population of Uveitis in the UK (2017–2030)

Table 47 Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Table 48 Gender-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Table 49 Age-specific Prevalent Population of Uveitis in the UK (2017–2030)

Table 50 Type-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Table 51 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2030)

Table 52 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2030)

Table 53 Prevalent Population of Uveitis in Japan (2017–2030)

Table 54 Diagnosed Prevalent Population of Uveitis in Japan (2017–2030)

Table 55 Gender-specific Prevalent Population of Uveitis in Japan (2017–2030)

Table 56 Age-specific Prevalent Population of Uveitis in Japan (2017–2030)

Table 57 Type-specific Prevalent Population of Uveitis in Japan (2017–2030)

Table 58 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2030)

Table 59 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2030)

Table 60 First Line of Therapy of the Treatment of Uveitis, 2020

Table 61 Marketed Drugs for Uveitis

Table 62 Tobradex, Clinical Trial Description, 2020

Table 63 Emerging Drugs Analysis

Table 64 ADX-102, Clinical Trial Description, 2020

Table 65 Sirolimus, Clinical Trial Description, 2020

Table 66 EGP 437, Clinical Trial Description, 2020

Table 67 Suprachoroidal CLS-TA, Clinical Trial Description, 2020

Table 68 Sarilumab, Clinical Trial Description, 2020

Table 69 LME636, Clinical Trial Description, 2020

Table 70 LFG316, Clinical Trial Description, 2020

Table 71 Abatacept, Clinical Trial Description, 2020

Table 72 EYS606, Clinical Trial Description, 2020

Table 73 Market size of Uveitis by Region in USD Million (2017–2030)

Table 74 Market Size of Uveitis by Therapies in 7MM, in USD Million (2017–2030)

Table 75 Market Size of Uveitis in the United States, USD Million (2017–2030)

Table 76 The United States Uveitis Market Size by Therapies in USD Million (2017–2030)

Table 77 Market Size of Uveitis in Germany, USD Million (2017–2030)

Table 78 Market Size of Uveitis by Therapies in Germany, in USD Million (2017–2030)

Table 79 Market Size of Uveitis in France, USD Million (2017–2030)

Table 80 Market Size of Uveitis by Therapies in France, in USD Million (2017–2030)

Table 81 Market Size of Uveitis in Italy, USD Million (2017–2030)

Table 82 Market Size of Uveitis by Therapies in Italy, in USD Million (2017–2030)

Table 83 Market Size of Uveitis in Spain, USD Million (2017–2030)

Table 84 Market Size of Uveitis by Therapies in Spain, in USD Million (2017–2030)

Table 85 Market Size of Uveitis in UK, USD Million (2017–2030)

Table 86 Market Size of Uveitis by Therapies in the United Kingdom, in USD Million (2017–2030)

Table 87 Market Size of Uveitis in Japan, USD Million (2017–2030)

Table 88 Market Size of Uveitis by Therapies in Japan, in USD Million (2017–2030)

List of Figures

 Figure 1 Structure of Eye

Figure 2 Types of Uveitis and Affected area

Figure 3 Classification of Uveitis

Figure 4 Types of Uveitis are based on the different parts of eye. Below are the four types

Figure 5 Symptoms of Uveitis

Figure 6 Pathogenetic mechanism of Uveitis

Figure 7 Mechanism of antigen processing and presentation.

Figure 8 Autoimmune conditions that cause uveitis

Figure 9 Causes of Uveitis

Figure 10 Diagnosis algorithm for Uveitis

Figure 11 Prevalent Population of Uveitis in the 7MM (2017–2030)

Figure 12 Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)

Figure 13 Type-specific Diagnosed Prevalent Population of Uveitis in the 7MM (2017–2030)

Figure 14 Total Prevalent Population of Uveitis in the United States (2017–2030)

Figure 15 Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)

Figure 16 Gender-specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)

Figure 17 Age-specific Diagnosed Prevalent Population of Uveitis in the United States (2017–2030)

Figure 18 Type-specific Diagnosed Prevalent Population of Uveitis in the US (2017–2030)

Figure 19 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the United States (2017–2030)

Figure 20 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the United States (2017–2030)

Figure 21 Prevalent Population of Uveitis in Germany (2017–2030)

Figure 22 Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Figure 23 Gender-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Figure 24 Age-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Figure 25 Type-specific Diagnosed Prevalent Population of Uveitis in Germany (2017–2030)

Figure 26 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Germany (2017–2030)

Figure 27 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Germany 2017–2030)

Figure 28 Prevalent Population of Uveitis in France (2017–2030)

Figure 29 Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Figure 30 Gender-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Figure 31 Age-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Figure 32 Type-specific Diagnosed Prevalent Population of Uveitis in France (2017–2030)

Figure 33 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in France (2017–2030)

Figure 34 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in France (2017–2030)

Figure 35 Prevalent Population of Uveitis in Italy (2017–2030)

Figure 36 Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Figure 37 Gender-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Figure 38 Age-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Figure 39 Type-specific Diagnosed Prevalent Population of Uveitis in Italy (2017–2030)

Figure 40 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Italy (2017–2030)

Figure 41 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Italy (2017–2030)

Figure 42 Prevalent Population of Uveitis & Non-Infectious Uveitis (NIU) in Spain (2017–2030)

Figure 43 Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Figure 44 Gender-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Figure 45 Age-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Figure 46 Type-specific Diagnosed Prevalent Population of Uveitis in Spain (2017–2030)

Figure 47 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Spain (2017–2030)

Figure 48 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Spain (2017–2030)

Figure 49 Prevalent Population of Uveitis in the UK (2017–2030)

Figure 50 Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Figure 51 Gender-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Figure 52 Age-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Figure 53 Type-specific Diagnosed Prevalent Population of Uveitis in the UK (2017–2030)

Figure 54 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in the UK (2017–2030)

Figure 55 Grade-specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in the UK (2017–2030)

Figure 56 Prevalent Population of Uveitis in Japan (2017–2030)

Figure 57 Diagnosed Prevalent Population of Uveitis in Japan (2017–2030)

Figure 58 Gender-specific Prevalent Population of Uveitis in Japan (2017–2030)

Figure 59 Age-specific Prevalent Population of Uveitis in Japan (2017–2030)

Figure 60 Type Specific Prevalent Population of Uveitis in Japan (2017–2030)

Figure 61 Diagnosed Prevalence of Non-infectious Uveitis (NIU) by Anatomical Location in Japan (2017-2030)

Figure 62 Grade-Specific Diagnosed Prevalence of Anterior noninfectious Uveitis (aNIU) in Japan (2017–2030)

Figure 63 Treatment Regimens

Figure 64 Treatment Algorithm of Uveitis

Figure 65 Therapeutic algorithm in endogenous Anterior Uveitis (AU)

Figure 66 Therapeutic algorithm in endogenous Intermediate Uveitis (IU)

Figure 67 Therapeutic algorithm in immune-mediated posterior uveítis or panuveiti

Figure 68 Management flowchart for non-infectious uveitis

Figure 69 Unmet Needs

Figure 70 Market size of Uveitis by Region in USD Million (2017–2030)

Figure 71 Market Size of Uveitis by Therapies in the 7MM, in USD Million (2017–2030)

Figure 72 Market Size of Uveitis in the United States, USD Million (2017–2030)

Figure 73 The United States Uveitis Market Size by Therapies in USD Million (2017–2030)

Figure 74 Market Size of Uveitis in Germany, USD Million (2017–2030)

Figure 75 Market Size of Uveitis by Therapies in Germany, in USD Million (2017–2030)

Figure 76 Market Size of Uveitis in France, USD Million (2017–2030)

Figure 77 France Uveitis Market Size by Therapies in USD Million (2017–2030)

Figure 78 Market Size of Uveitis in Italy, USD Million (2017–2030)

Figure 79 Italy Uveitis Market Size by Therapies in USD Million (2017–2030)

Figure 80 Market Size of Uveitis in Spain, USD Million (2017–2030)

Figure 81 Spain Uveitis Market Size by Therapies in USD Million (2017–2030)

Figure 82 Market Size of Uveitis in United Kingdom, USD Million (2017–2030)

Figure 83 United Kingdom Uveitis Market Size by Therapies in USD Million (2017–2030)

Figure 84 Market Size of Uveitis in Japan, USD Million (2017–2030)

Figure 85 Japan Uveitis Market Size by Therapies in USD Million (2017–2030)

Figure 86 Market Drivers of Uveitis

Figure 87 Market Barriers of Uveitis

Figure 88 KOL Views

Figure 89 United States KOL Views Uveitis

Figure 90 EU5 KOL Views

Sirion Therapeutics

Novartis

Valeant Pharmaceuticals International Inc

Aldeyra Therapeutics

Santen

EyeGate Pharmaceuticals

And Many Other

  • Tags:
  • Uveitis market
  • Uveitis market research
  • Uveitis market insight
  • Uveitis market trends
  • Uveitis market forecast
  • Uveitis market share
  • Uveitis pipeline drugs
  • Uveitis treatment algorithm
  • Uveitis drugs
  • Uveitis sales forecasting
  • Uveitis market size
  • Uveitis disease
  • Uveitis epidemiology
  • Uveitis

Forward to Friend

Need A Quote